98
edits
Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
Programmed death-ligand 1 (view source)
Revision as of 04:53, 13 November 2017
, 04:53, 13 November 2017→Anti-PD-L1 drugs - use
| Line 37: | Line 37: | ||
**Associated with response predicted by [[tumour-infiltrating lymphocytes]] and ''PD-L1 IHC'' positivity of the tumour cells.<ref name=pmid26970723/> | **Associated with response predicted by [[tumour-infiltrating lymphocytes]] and ''PD-L1 IHC'' positivity of the tumour cells.<ref name=pmid26970723/> | ||
*[[Renal cell carcinoma]]. | *[[Renal cell carcinoma]]. | ||
*[[Urothelial carcinoma]]. | |||
==See also== | ==See also== | ||